Turteltaub K W, Mauthe R J, Dingley K H, Vogel J S, Frantz C E, Garner R C, Shen N
Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Mutat Res. 1997 May 12;376(1-2):243-52. doi: 10.1016/s0027-5107(97)00049-3.
Heterocyclic amines, such as 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), are mutagenic/carcinogenic compounds formed during the cooking of protein-rich foods. Human exposure to MeIQx has been estimated to range from ng/person/day to a few microgram/person/day. In contrast, animal studies have been conducted at doses in excess of 10 mg/kg/day. In order to determine the relevance of high-dose animal data for human exposure, the dose-response curves for [14C]-MeIQx have been determined in rodents at low doses under both single-dose and chronic dosing regimens using the high sensitivity of accelerator mass spectrometry (AMS). To make a direct species comparison, rodent and human colonic MeIQx-DNA adduct levels have been compared following oral administration of [14C]-MeIQx. The results of these studies show: (1) total MeIQx levels are highest in the liver > kidney > pancreas > intestine > blood; (2) MeIQx levels in the liver plateau after 7 days of chronic feeding; (3) hepatic MeIQx-DNA adducts begin to plateau after 2-4 weeks and reach steady-state levels between 4 and 12 weeks on chronic exposures; (4) hepatic DNA adducts generally increase as a linear function of administered dose for a single-dose exposure and as a power function for chronic feeding over a dose range spanning 4 orders of magnitude; (5) human colon DNA adduct levels are approximately 10 times greater than in rodents at the same dose and time point following exposure; and (6) > or = 90% of the MeIQx-DNA adduct in both rodent and human colon appears to be the dG-C8-MeIQx adduct. These studies show that MeIQx is readily available to the tissues for both humans and rodents and that adduct levels are generally linear with administered dose except at high chronic doses where adduct levels begin to plateau slightly. This plateau indicates that linear extrapolation from high-dose studies probably underestimates the amount of DNA damage present in the tissues following low dose. Further, if adducts represent the biologically effective dose, these data show that human colon may be as sensitive to the genotoxic effects of MeIQx as rat liver. The significance of these endpoints to tumor response remains to be determined.
杂环胺,如2-氨基-3,8-二甲基咪唑并[4,5-f]喹喔啉(MeIQx),是在富含蛋白质食物烹饪过程中形成的诱变/致癌化合物。据估计,人类接触MeIQx的量范围为每人每天纳克到几微克。相比之下,动物研究的剂量超过了每天10毫克/千克。为了确定高剂量动物数据与人类接触的相关性,利用加速器质谱(AMS)的高灵敏度,在单剂量和慢性给药方案下,在低剂量的啮齿动物中测定了[14C]-MeIQx的剂量反应曲线。为了进行直接的物种比较,在口服给予[14C]-MeIQx后,比较了啮齿动物和人类结肠中MeIQx-DNA加合物水平。这些研究结果表明:(1)MeIQx的总水平在肝脏中最高>肾脏>胰腺>肠道>血液;(2)慢性喂养7天后肝脏中的MeIQx水平趋于平稳;(3)肝脏中MeIQx-DNA加合物在2-4周后开始趋于平稳,并在慢性暴露4至12周之间达到稳态水平;(4)对于单剂量暴露,肝脏DNA加合物通常随给药剂量呈线性增加,对于跨越4个数量级的剂量范围的慢性喂养,呈幂函数增加;(5)在相同剂量和暴露时间点,人类结肠DNA加合物水平比啮齿动物高约10倍;(6)啮齿动物和人类结肠中>或=90%的MeIQx-DNA加合物似乎是dG-C8-MeIQx加合物。这些研究表明,MeIQx对人类和啮齿动物的组织来说都很容易获得,并且加合物水平通常与给药剂量呈线性关系,除了在高慢性剂量下加合物水平开始略有平稳。这种平稳表明,从高剂量研究进行线性外推可能低估了低剂量后组织中存在的DNA损伤量。此外,如果加合物代表生物学有效剂量,这些数据表明人类结肠对MeIQx的遗传毒性作用可能与大鼠肝脏一样敏感。这些终点对肿瘤反应的意义仍有待确定。